The Technical Analyst
Neuronetics Inc [STIM]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Neuronetics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.52% $3.97
America/New_York / 19 apr 2024 @ 13:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 117.98 mill |
| EPS: | -1.050 |
| P/E: | -3.78 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 29.76 mill |
| Avg Daily Volume: | 0.179 mill |
| RATING 2024-04-19 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.78 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.20x |
| Company: PE -3.78 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.61 - 4.32 ( +/- 8.93%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-29 | Macan William Andrew | Buy | 15 000 | Common Stock |
| 2024-02-28 | Macan William Andrew | Sell | 22 377 | Common Stock |
| 2024-02-29 | Macan William Andrew | Sell | 6 026 | Common Stock |
| 2024-02-29 | Furlong Stephen | Buy | 15 000 | Common Stock |
| 2024-02-27 | Furlong Stephen | Sell | 21 272 | Common Stock |
| INSIDER POWER |
|---|
| 17.31 |
| Last 100 transactions |
| Buy: 1 892 506 | Sell: 1 430 741 |
Forecast:
15:57 - $3.96
Live Trading Signals (every 1 min)
Forecast
1: 14:27 - $3.96
Forecast 2: 15:17 - $4.02
Forecast 3: 15:57 - $3.96
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.97 (3.52% ) |
| Volume | 0.0255 mill |
| Avg. Vol. | 0.179 mill |
| % of Avg. Vol | 14.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For STIM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Latest Press Releases
2024-04-10 08:31:00 - Press Release
New Publication In Brain Stimulation Confirms Full Tms Treatment Course Is Vital
Lack of early symptom improvement is not predictive of final responder status lack of early symptom improvement is not predictive of final responder status
2024-03-27 16:30:00 - Press Release
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Malvern, pa., march 27, 2024 (globe newswire) -- neuronetics, inc. (nasdaq: stim), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of restricted stock units representing a total of 135,000 shares of the company's common stock (rsus) to eleven new non-executive employees. in accordance with nasdaq listing rule 5635(c)(4), these awards were approved by neuronetics' compensation committee and made as material inducements to their respective employment with the company.
2024-03-25 08:30:00 - Press Release
Neurostar® Advanced Therapy Receives Fda Clearance As A First-line Add-on Treatment For Adolescents With Depression
Neurostar is the first and only tms therapy cleared as an adjunct treatment for patients ages 15 and older neurostar is the first and only tms therapy cleared as an adjunct treatment for patients ages 15 and older
2024-03-07 08:22:00 - Press Release
Neuronetics Announces 5-year Exclusive Partnership With Transformations Care Network
Malvern, pa., march 07, 2024 (globe newswire) -- neuronetics, inc. (nasdaq: stim), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with transformations care network ("tcn"), one of the nation's largest mental health care providers. under the new agreement, neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (tms) equipment to tcn, increasing its neurostar tms footprint and availability to patients.
2024-03-05 07:30:00 - Press Release
Neuronetics Reports Record Fourth Quarter And Record Full Year 2023 Financial And Operating Results
Malvern, pa., march 05, 2024 (globe newswire) -- neuronetics, inc. (nasdaq: stim) (the “company” or “neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2023.
Latest News
2024-04-01 11:56:10 - Zacks Investment Research
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
2024-03-08 09:11:16 - Zacks Investment Research
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
2024-03-05 09:41:04 - Zacks Investment Research
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
2024-02-20 08:30:00 - GlobeNewsWire
Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2023 financial and operating results prior to market open on Tuesday, March 5th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
2023-11-15 16:15:00 - GlobeNewsWire
Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference
MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. The Company is scheduled to present at 2:00 pm Eastern Time the same day via webcast.
2023-10-24 08:30:00 - GlobeNewsWire
Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter 2023 financial and operating results prior to market open on Tuesday, November 7th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
2023-09-06 17:26:45 - Seeking Alpha
Neuronetics: Large Losses May Be Repelling Investors
Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability. While market conditions appear to have stabilized somewhat, Neuronetics still needs to rein in operating expenses. Neuronetics' current valuation is near all-time lows, which may present an opportunity. Competition and reliance on large investments in sales and marketing present risks though.
2023-08-08 12:59:18 - Seeking Alpha
Neuronetics, Inc. (STIM) Q2 2023 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Zachary Day - Canaccord Simran Kaur - Piper Sandler Daniel Stauder - JMP Securities Operator Thank you for standing by, welcome to the Neuronetics Second Quarter 2023 Financial and Operating Results Conference Call. At this time al participants' are in a listen-only mode.
2023-07-25 08:30:00 - GlobeNewsWire
Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release second quarter 2023 financial and operating results prior to market open on Tuesday, August 8th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
2023-05-24 16:30:00 - GlobeNewsWire
Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference
MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023. The Company is scheduled to present at 1:00 pm Eastern Time the same day via webcast.